Red blood cells develop in the bone marrow, which is the sponge-like tissue inside your bones. Your body normally destroys old or faulty red blood cells in the anemia occurs when you have a low number of red blood cells due to too much hemolysis in the body.or other parts of your body through a process called . Hemolytic
There are many types of hemolytic anemia, which doctors diagnose based on the underlying cause of your anemia. Certain conditions can cause hemolysis to happen too fast or too often. Conditions that may lead to hemolytic anemia include sickle cell disease or thalassemia, disorders, bone marrow failure, or infections. Some medicines or side effects to blood transfusions may cause hemolytic anemia.blood disorders such as
Hemolytic anemia can develop suddenly or slowly, and it can be mild or severe. heart palpitations, pale skin, headache, confusion, jaundice, and a spleen or liver that is larger than normal. Severe hemolytic anemia can cause chills, fever, pain in the back and abdomen, or . Severe hemolytic anemia that is not treated or controlled can lead to serious complications, such as irregular heart rhythms called arrhythmias; cardiomyopathy, in which the heart grows larger than normal; or heart failure.and may include , dizziness,
To diagnose hemolytic anemia, your doctor will do a physical exam and order blood tests. Additional tests may include a urine test, a bone marrow test, or tests. People who are diagnosed with mild hemolytic anemia may not need treatment at all. For others, hemolytic anemia can often be treated or controlled. Treatments may include lifestyle changes, medicines, blood transfusions, blood and bone marrow transplants, or surgery to remove the spleen. If your hemolytic anemia is caused by medicines or another health condition, your doctor may change your treatment to control or stop the hemolytic anemia.
Visit Hemolytic Anemia for more information about this topic.
Improving health with current research
- Hemolytic Anemia
Learn about the following ways the NHLBI continues to translate current research into improved health for people who have hemolytic anemia. Research on this topic is part of the NHLBI’s broader commitment to advancing blood disorders and blood safety through scientific discovery.
- Program Helps Protect Blood Transfusion Recipients. The NHLBI’s Recipient Epidemiology and Donor Evaluation Study (REDS) program began in 1989 to protect the Nation’s blood supply and improve the benefits and reduce the risks of transfusions. Now in its third phase, called REDS-III, the program supports research in the United States and around the world.
- Providing Access to NHLBI Biologic Specimens and Data. The Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) centralizes and integrates biospecimens and clinical data that were once stored in separate repositories. Researchers can find and request available resources on BioLINCC’s secure website, which maximizes the value of these resources and advances heart, lung, blood, and sleep research.
- New Treatments for Hemolytic Anemia. NHLBI-sponsored clinical trials showed that eculizumab is an effective treatment for a rare and life-threatening type of hemolytic anemia called paroxysmal nocturnal hemoglobinuria (PNH). Eculizumab can reduce or stop the need for blood transfusions. NHLBI research helped eculizumab become the standard treatment for PNH.
- Supporting Safe Manufacturing of Cell-Based Therapies. The NHLBI’s Production Assistance for Cellular Therapies (PACT) program supports translational research on cellular and genetic therapies by increasing the capacity to manufacture cell products that follow current Good Manufacturing Practices (cGMP) regulations. The PACT program aims to increase the supply and safety of genetically modified cells available for people who have blood disorders such as hemolytic anemia.
- Accelerating Cures for All People Who Have Sickle Cell Disease. Our Cure Sickle Cell Initiative is a NHLBI-led collaborative research effort to develop genetic therapies for patients who have sickle cell disease. The goal is to have these genetic therapies ready to safely use in clinical research within 5 to 10 years. This patient-focused Initiative will bring together researchers, private sector researchers, patients, providers, advocacy groups, and others as it supports research, education, and community engagement activities.
- Improving Care for Adolescents and Adults Who Have Sickle Cell Disease. While most U.S. children who have sickle cell disease survive to adulthood, the transition from pediatric to adult care is often challenging. By funding the Sickle Cell Disease Implementation Consortium, we are working to understand current barriers to care, test interventions to overcome those barriers, and develop a new sickle cell disease registry.
- Network Accelerates Research on Blood and Bone Marrow Transplants. The NHLBI and NCI launched the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) in 2001 to promote large multi-institutional clinical trials that seek to understand the best possible treatment approaches in blood and marrow transplantation. In the United States, about 20,000 patients receive blood or marrow transplants annually.
Advancing research for improved health
- Hemolytic Anemia
In support of our mission, we are committed to advancing hemolytic anemia research in part through the following ways.
- We perform research. The NHLBI Division of Intramural Research and its Hematology Branch are actively engaged in research on conditions related to hemolytic anemia. Research in the Hematopoiesis and Bone Marrow Failure Laboratory spans the basic sciences, clinical trials, and epidemiology, focusing on blood cell production in healthy individuals and patients who have bone marrow failure.
- We fund research. The research we fund today will help improve our future health. Our Division of Blood Diseases and Resources is a leader in research on the causes, prevention, and treatment of blood diseases, including hemolytic anemia and sickle cell disease. Search the NIH RePORTer to learn about research the NHLBI is funding on hemolytic anemia.
- We stimulate high-impact research. The NHLBI Strategic Vision highlights ways we may support research on hemolytic anemia over the next decade.
Learn about exciting research areas the NHLBI is exploring about hemolytic anemia.
- Preventing complications from hemolytic anemia. During hemolytic anemia, red blood cells release heme molecules into the blood. These heme molecules may become toxic because they are no longer bound by protective proteins. They may also collect in organs, such as the kidneys, and cause damage. NHLBI-supported researchers are looking into treatments that may be able to prevent this damage.
- Supporting research on rare types of hemolytic anemia. We support research on new treatments for a rare type of cold agglutinin disease. hemolytic anemia called
- Understanding rare but life-threatening reactions to blood transfusions. Some people are more at risk of developing hemolytic reactions to a blood transfusion even when the blood type is matched. The NHLBI supports research to identify the cause, predict people who have a greater risk, and find treatments that prevent hemolytic anemia.
We lead or sponsor many studies on different types of hemolytic anemia. See if you or someone you know is eligible to participate in our.
Do you have a critically ill child in the ICU?
Are you considering a blood stem cell transplant?
Are you or your child interested in donating a sample of bone marrow for research?
Have you received a stem cell transplant?
Do you want to take part in blood research?
Would you like to participate in studies on blood disorders?
Are you scheduled for a stem cell transplant with cord blood?
After reading our Hemolytic Anemia Health Topic, you may be interested in additional information found in the following resources.
Related Health Topics
- Hemolytic Anemia
- Hemolytic Anemia
- Anemia (National Library of Medicine [NLM], MedlinePlus)
- Autoimmune hemolytic anemia (Genetic and Rare Diseases Information Center [GARD], National Center for Advancing Translational Sciences [NCATS], NIH)
- Cold agglutinin disease (GARD, NCATS)
- Drugs that should be avoided with G6PD deficiency (G6PD Favism Association)
- Evans syndrome (GARD, NCATS)
- G6PD deficiency (NLM, MedlinePlus)
- Hemoglobin Zurich (GARD, NCATS)
- Hemolytic anemia (NLM, MedlinePlus)
- Hemolytic uremic syndrome (GARD, NCATS)
- Paroxysmal nocturnal hemoglobinuria (GARD, NCATS)
- Warm antibody hemolytic anemia (GARD, NCATS)